Financial Considerations Under the terms of the merger agreement, Sanofi will acquire DR-0201 through the acquisition of the Dren Bio affiliate Dren-0201 for an upfront payment of $600 million and ...

Sanofi SA is getting deeper into oncology and immunology therapy development through buying Dren Bio Inc.’s myeloid cell engager for deep B-cell depletion, DR-0201. The deal could reach as high as $1.

Sanofi to pay $600 million upfront payment to buy Dren Bio's bispecific myeloid cell engager, DR-0201: Paris Friday, March 21, 2025, 09:00 Hrs [IST] Sanofi and Dren Bio, Inc., a p ...

The deal with startup Dren Bio hands Sanofi a so-called myeloid cell engager that would compete with an array of programs ...

Novel CAR T cells and cord blood-derived CAR NK cells for relapsed acute myeloid leukemia after allogeneic ... Japan Agency for Medical Research and Development (AMED), Chemo-Sero- Therapeutic ...

Specifically, there was an accumulation of common myeloid progenitors (CMPs), which ... Very little was known about how they ...

Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell engager, from Dren Bio Inc. for $600 million upfront ...

Sanofi and Dren Bio, Inc., a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid ...

Without PSPC1, myeloid cell differentiation resumed ... 1, a transcription factor essential for blood and immune cell development. This interaction activated tumor-promoting genes, including ...

Therefore, effectively engaging and activating macrophages to kill cancer cells offers ... company pursuing the development of novel therapies, with the company’s novel Myeloid Engager Platform ...